Trials / Completed
CompletedNCT04314986
Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882, a Potent Uricosuric Agent, in Healthy Adult Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A study to assess multiple ascending doses of AR882 in healthy adult males.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cohort 1: AR882 or placebo | AR882 or matching placebo administered once daily for 10 days |
| DRUG | Cohort 2: AR882 or placebo | AR882 or matching placebo administered once daily for 10 days. |
| DRUG | Cohort 3: AR882 or placebo | AR882 or matching placebo administered once daily for 10 days |
| DRUG | Cohort 4: AR882 or placebo | AR882 or matching placebo administered once daily for 10 days |
Timeline
- Start date
- 2019-06-28
- Primary completion
- 2019-09-18
- Completion
- 2019-09-18
- First posted
- 2020-03-19
- Last updated
- 2020-11-16
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04314986. Inclusion in this directory is not an endorsement.